^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MIR106A (MicroRNA 106a)

i
Other names: MIR106A, MicroRNA 106a, Hsa-MiR-106a-5p, Hsa-MiR-106a-3p, Hsa-Mir-106a, Mir-106a, MIRN106A, Mir-106
21d
The circTIMP2/miR-106a/TIMP2 tumor-suppressive axis versus tumor-derived exosomal counteraction in gastric cancer. (PubMed, Apoptosis)
Importantly, tumor-derived exosomes counteracted the suppressive effects of circTIMP2, promoting orthotopic tumor progression by inhibiting TIMP2 and reactivating Wnt/β-catenin signaling. Our findings unveil a novel circRNA-guided feedback loop in gastric cancer and highlight how exosome-mediated mechanisms counteract this axis, providing new insights into the molecular pathogenesis of gastric cancer and suggesting potential therapeutic targets.
Journal
|
TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MIR106A (MicroRNA 106a)
28d
Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma. (PubMed, Int J Mol Sci)
These molecules may serve as diagnostic and prognostic biomarkers. Their potential as therapeutic targets requires further mechanistic and translational investigation.
Clinical • Journal
|
HMGB1 (High Mobility Group Box 1) • HMGA1 (High Mobility Group AT-Hook 1) • HMGA2 (High mobility group AT-hook 2) • MIR106A (MicroRNA 106a)
3ms
Upregulation of a MicroRNA Signature Involving miR-17-5p, miR-26b-5p, miR-106a-5p, and miR-146a-5p During Cervical Epithelial Transformation. (PubMed, Epigenomes)
The gradual increase in specific miRNAs with lesion severity and HPV infection suggests their role in cervical carcinogenesis. The identified miRNAs may serve as promising non-invasive biomarkers for early detection and monitoring of HPV-associated cervical lesions.
Journal
|
MIR155 (MicroRNA 155) • MIR106A (MicroRNA 106a) • MIR17 (MicroRNA 17) • MIR191 (MicroRNA 191) • MIR29A (MicroRNA 29a)
3ms
A miRNA screen reveals a transcriptional network controlling the initiation of mammary organoids. (PubMed, FEBS J)
Extending these findings to cancer, we demonstrate that enforced expression of miR-106a-3p significantly increases tumoroid formation, suggesting that the tumor microenvironment, as modeled by 3D culture, promotes miR-106a-3p expression and functional relevance in tumorigenic processes. Collectively, these data indicate that miR-106a-3p drives a transient expansion of progenitor-like states and orchestrates transcriptional reprogramming during organoid initiation, with broader implications for breast tissue homeostasis and pathophysiological remodeling in cancer.
Journal
|
GATA3 (GATA binding protein 3) • MIR106A (MicroRNA 106a)
3ms
Assessment of miRNA 106a-5p and 375-3p Expression in the Context of the Wnt/β-Catenin Pathway-Comparison of Prostate Adenocarcinoma and Benign Prostatic Hyperplasia Tissues. (PubMed, Int J Mol Sci)
Our study results revealed lower immunoreactivity and expression of genes encoding β-catenin, Fzd8, Wnt5a, and cyclin D1 and significantly higher fluorescence intensity of miRNA 106a-5p and 375-3p with prostate adenocarcinoma compared to BPH. These parallel alterations in miRNA expression and Wnt/β-catenin-related components reflect disease-specific expression patterns and warrant further investigation in larger cohorts to determine their potential utility as diagnostic biomarkers in prostate diseases.
Clinical • Journal
|
CCND1 (Cyclin D1) • MIR106A (MicroRNA 106a) • MIR375 (MicroRNA 375)
3ms
The HPV-E7/miR-106a/RUNX3/TGF-β1 axis regulates malignant progression in both HPV-positive and negative head and neck squamous cell carcinoma. (PubMed, Mol Cell Probes)
Our findings suggest that the E7/miR-106a/RUNX3/TGF-β1 axis modulates proliferation, migration, invasion, and apoptosis in HPV-positive versus negative HNSCC, implicating its pathogenic role in tumor progression.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • RUNX3 (RUNX Family Transcription Factor 3) • MIR106A (MicroRNA 106a)
4ms
Comprehensive Transcriptome and miRNome Profiling in Metachronous Colorectal Liver Metastasis: Insight into the Prognostic and Molecular Subtypes. (PubMed, Lab Invest)
The miRNA-mRNA interactions were validated using real-time PCR in independent patient cohorts. This study revealed a complex molecular landscape of mCLM within the hepatic microenvironment and novel miRNA-mRNA interactions with potential prognostic and therapeutic implications.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MIR21 (MicroRNA 21) • MIR7 (MicroRNA 7) • Let-7c (MicroRNA Let-7c) • MIR106A (MicroRNA 106a) • MIR139 (MicroRNA 139) • MIR20B (MicroRNA 20b) • MIR320A (MicroRNA 320a) • MIR660 (MicroRNA 660) • MIR1304 (MicroRNA 1304) • MIR320B (MicroRNA 320b)
|
KRAS mutation
5ms
A long non-coding RNA SCAMP1 induces pancreatic ductal adenocarcinoma progression through miR-106a-5p/AGK signaling. (PubMed, Clin Exp Med)
Knockdown of SCAMP1 expression reduced tumor cell growth, invasion, epithelial‑mesenchymal transition (EMT), and improved sensitivity to 5-fluorouracil (5-FU) in vitro and inhibited tumor cell xenograft growth in nude mice...The data from the current study demonstrated an oncogenic SCAMP1 activity in PDAC. Further study will investigate SCAMP1 as a tumor biomarker and novel target in control of PDAC clinically.
Journal
|
AGK (Acylglycerol Kinase) • GK (Glycerol Kinase) • MIR106A (MicroRNA 106a)
|
5-fluorouracil
5ms
Circular RNA circNRIP1 promotes glioma progression by regulating the miR-106a-5p/GPR133 pathway. (PubMed, Sci Rep)
circNRIP1 knockdown suppresses glioma progression by elevating miR-106a-5p levels and simultaneously reducing GPR133 expression. The identified circNRIP1/miR-106a-5p/GPR133 axis could potentially be a therapeutic target for glioma.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • MIR106A (MicroRNA 106a)
7ms
Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer. (PubMed, Front Oncol)
The study highlights differential regulation of circulating and tissue miRNAs in Indian OC patients, emphasizing the selective retention of oncogenic miRNAs in tumors and release of tumor suppressive miRNAs into circulation. These findings support the utility of miRNAs as diagnostic and prognostic biomarkers in OC.
Journal
|
MIR200A (MicroRNA 200a) • MIR106A (MicroRNA 106a) • MIR182 (MicroRNA 182) • MIR23b (MicroRNA 23b) • MIR130A (MicroRNA 130a) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a) • MIR433 (MicroRNA 433)
8ms
MLR Corresponds to the Functional Status of Monocytes in Chronic Lymphocytic Leukemia. (PubMed, Int J Inflam)
The MLR index may serve not only as a marker of CLL activity, but also indirectly indicate changes in the phenotype and function of monocyte subpopulations present in the blood microenvironment. Moreover, the MLR-high parameter seems to correspond to an increase in the percentage of intermediate monocytes with anti-inflammatory properties, which may potentially promote disease progression and worsen its prognosis.
Journal • IO biomarker
|
CD38 (CD38 Molecule) • CD5 (CD5 Molecule) • IL10 (Interleukin 10) • MIR21 (MicroRNA 21) • MIR106A (MicroRNA 106a) • MIR150 (MicroRNA 150)
9ms
Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment. (PubMed, Hematology)
MiR-106a and miR-20a are promising AML prognostic biomarkers for adverse outcome. The combined signature improves risk stratification and guides therapy selection (e.g., ⁣allo-HSCT for high-risk cases).
Journal
|
MIR106A (MicroRNA 106a) • MIR17 (MicroRNA 17) • MIR20A (MicroRNA 20a)